Pfizer Paxlovid prescriptions to treat Covid increased tenfold in US since late February

Read Time:3 Minute, 18 Second


Pfizer on Tuesday said prescriptions for its oral antiviral to treat Covid-19 have increased tenfold in the US since late February, as more pharmacies and other locations receive supply.

CEO Albert Bourla, in an earnings call Tuesday morning, said nearly 80,000 patients were treated with Paxlovid in the US the week ending April 22, up from about 8,000 patients in late February. More than 33,000 sites in the US now have supply of Paxlovid, Bourla said, a fourfold increase over February.

Shares of Pfizer were up over 1% in Tuesday afternoon trading.

Paxlovid supply was constrained when the antiviral first rolled out over the winter, but Pfizer is ramping up production with 6 million courses produced through the end of March, according to Bourla. Pfizer is on track to manufacture 30 million courses in the first half of 2022 and 120 million by the end of the year, Bourla said.

Pfizer on Tuesday reported $1.5 billion in Paxlovid sales for the first quarter and maintained its guidance of $22 billion in sales for 2022. Angela Hwang, Pfizer’s head of biopharmaceuticals, told analysts Tuesday that demand for the antiviral will increase as nations reorder doses and lower the eligibility age.

Covid transmission will increase as governments ease public health restrictions, and Paxlovid will play an important role in treating people who get infected, Hwang said. Pfizer doesn’t have any inventory on hand because every dose manufactured gets shipped, she said.

The US has ordered a total of 20 million Paxlovid courses, with the delivery of the first 10 million courses to be completed in June and fulfillment of the second 10 million scheduled for September, according to the Biden administration. Patients in the US had used more than 500,000 Paxlovid courses as of late April, a senior administration official told reporters last month.

The White House is ramping up distribution of Paxlovid as a key component of its strategy to fight Covid. The Health and Human Services Department aims to bring the antiviral to 40,000 locations across the nation. The US has set up at least 2,200 sites where people can receive Paxlovid as soon as they test positive for the virus, including pharmacies, community health centers and long-term care facilities.

The Food and Drug Administration authorized Paxlovid in December for adults and children ages 12 and older who are infected with Covid and at risk of severe illness from the virus. The FDA authorized Merck’s molnupiravir shortly after, but said it should only be used for adults ages 18 and over who don’t have access to Paxlovid or other Covid treatments.

Paxlovid proved more effective and had a better safety profile than molnupiravir in clinical trials. Pfizer’s antiviral reduced the risk of hospitalization or death by 90% in adults who had Covid and were at risk of developing severe illness. Molnupiravir reduced the risk of hospitalization and death by 30% in clinical trials among Covid patients at risk of severe illness.

Paxlovid now has a 90% market share compared to Merck’s molnupiravir in the US retail pharmacy, long-term care and mail order markets, Bourla said. The antiviral is now authorized in more than 60 countries and Pfizer is in discussions to bring the treatment to additional markets, he said.

Patients prescribed Paxlovid take a three tablet course twice daily for five days. The course includes two nirmatrelvir pills, developed by Pfizer, and one tablet of ritonavir, a widely used HIV drug. Nirmatrelvir inhibits an enzyme the Covid virus uses to reproduce and ritonavir slows the patient’s metabolism to the medication remains active in the body for a longer period.

While Paxlovid is effective at preventing hospitalization and death in people who already have Covid, it failed to prevent infection from the virus in clinical trial results published Friday.


If you want to know more about business please go to https://updatednews24.com/category/business/

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. View more
Cookies settings
Accept
Privacy & Cookie policy
Privacy & Cookies policy
Cookie name Active

Who we are

Suggested text: Our website address is: https://updatednews24.com.

Comments

Suggested text: When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection. An anonymized string created from your email address (also called a hash) may be provided to the Gravatar service to see if you are using it. The Gravatar service privacy policy is available here: https://automattic.com/privacy/. After approval of your comment, your profile picture is visible to the public in the context of your comment.

Media

Suggested text: If you upload images to the website, you should avoid uploading images with embedded location data (EXIF GPS) included. Visitors to the website can download and extract any location data from images on the website.

Cookies

Suggested text: If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year. If you visit our login page, we will set a temporary cookie to determine if your browser accepts cookies. This cookie contains no personal data and is discarded when you close your browser. When you log in, we will also set up several cookies to save your login information and your screen display choices. Login cookies last for two days, and screen options cookies last for a year. If you select "Remember Me", your login will persist for two weeks. If you log out of your account, the login cookies will be removed. If you edit or publish an article, an additional cookie will be saved in your browser. This cookie includes no personal data and simply indicates the post ID of the article you just edited. It expires after 1 day.

Embedded content from other websites

Suggested text: Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website. These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.

Who we share your data with

Suggested text: If you request a password reset, your IP address will be included in the reset email.

How long we retain your data

Suggested text: If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue. For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.

What rights you have over your data

Suggested text: If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.

Where we send your data

Suggested text: Visitor comments may be checked through an automated spam detection service.
Save settings
Cookies settings